When a biotech appoints a new Chief Medical Officer, they are not hiring one person. They are hiring the twelve people that CMO is about to bring in over the following year. Recruiters who understand this get the call. Everyone else finds out when the roles are already filled.
Why leadership changes predict hiring so reliably
New executives rebuild. It is almost a law of the industry.
A new CMO arrives with a mandate to fix or scale clinical development, and within a few months they are hiring medical directors, clinical operations leaders, and pharmacovigilance staff. A new Chief Business Officer builds out BD. A new Head of Regulatory brings in people they trust. A new CEO reshapes the entire leadership layer.
None of this is speculative. It is the single most predictable pattern in life science hiring, and it is announced publicly, in a press release, weeks before the hiring starts.
The ninety-day window
New executives are unusually reachable in their first months, and unusually open to new vendors, for a specific reason: they have no established relationships at this company yet. The incumbent recruiter belonged to their predecessor. Everything is genuinely up for grabs in a way it will never be again.
A recruiter who reaches out in month two, with a credible understanding of the function and the talent market, is talking to someone actively deciding who to work with. A recruiter who reaches out in month ten is talking to someone who already has a firm.
Reading the announcement properly
- The function tells you what will be hired. Clinical, regulatory, commercial, manufacturing, each rebuilds differently.
- Where they came from tells you a lot about what they will want and who they might bring.
- The company’s stage tells you the scale of the build. A company approaching launch will hire aggressively across commercial and medical affairs.
- What else is happening matters. A leadership change plus a recent funding round plus an approaching filing is a hiring wave, not a hire.
The outreach that lands
Not “congratulations on the new role.” Every recruiter sends that, and it is transparently a prospecting email.
Instead: demonstrate that you know their function’s talent market, that you understand what a build looks like at their stage, and that you can reach the specific people they will need. You are offering something they are about to need urgently and have not yet solved.
Know who to call
A new CMO started somewhere this month and is already sketching the org chart. In ninety days, that team is being hired. Be in the conversation now.
Get Signals for your BD team, $8,000/year for up to 5 seats
Or a single seat, $2,500/year
Every Friday: 15 to 20 tagged signals, a “Who To Call This Week” list of 10 prioritized targets with the trigger and a suggested opening line, and a monthly outreach playbook. Two-week free trial, no commitment. See also the buying signals biotech vendors keep missing.
Frequently asked questions
Why are leadership changes a recruiting signal?
Because new executives rebuild. A new CMO typically hires medical directors, clinical operations leaders and pharmacovigilance staff within months. A new CBO builds out business development. It is the most predictable pattern in life science hiring, and it is announced publicly weeks before the hiring begins.
What is the window for reaching a new executive?
Roughly the first ninety days. New executives have no established vendor relationships at their new company, since the incumbent recruiter belonged to their predecessor, so everything is genuinely open in a way it will never be again. By month ten they have already chosen a firm.
How should a recruiter approach a newly appointed executive?
Not with congratulations, which every recruiter sends and which reads transparently as prospecting. Instead demonstrate knowledge of their function’s talent market, understanding of what a team build looks like at their company’s stage, and the ability to reach the specific people they will need, since that is a problem they are about to face urgently.
